You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
萬泰生物(603392.SH):終止授權賽諾菲進行新型輪狀病毒疫苗開發、生產及商業化
格隆匯 12-28 18:22

格隆匯12月28日丨萬泰生物(603392.SH)公佈,此前公吿披露,公司全資子公司廈門萬泰滄海生物技術有限公司(“萬泰滄海”)2020年7月28日與賽諾菲巴斯德公司(“賽諾菲”)簽署許可協議,授權賽諾菲進行新型輪狀病毒疫苗(主要用於預防A型輪狀病毒引起的兒童腹瀉)開發、生產及商業化。交易標的為新型輪狀病毒相關知識產權,交易金額為預付款及里程碑款總金額6800萬美元,其中包括1000萬美元預付款及5800萬美元里程碑付款,商業化後視銷售產品品種給予淨銷售額1%或2%的許可費。按照協議約定,賽諾菲應在合同簽署生效後30工作日內預付授權許可費1000萬美元,萬泰滄海於2020年8月31日收到該筆款項。

萬泰滄海近日收到賽諾菲發來的《關於終止新型輪狀病毒疫苗許可協議的通知函》,根據許可協議約定,賽諾菲有權出於任何原因,通過提前至少180日發出書面通知的方式終止該協議,該終止行為不屬於違約。本次交易終止將在該通知日期後的180日生效。在終止生效日期到期前,賽諾菲將銷燬所有從萬泰滄海獲取的許可產品、許可專有技術、許可材料和其他保密信息。

萬泰滄海已根據協議約定於2020年8月31日收到賽諾菲支付的預付授權許可費1000萬美元並履行了相關義務,此次交易的終止不影響該筆款項的收取權利,不會對公司收益產生影響。

截至目前,新型輪狀病毒的相關研究尚處於前期階段,根據公司產品開發戰略,暫未對其進行商業化產品開發,該交易的終止不會對公司整體業務發展和經營產生重大不利影響。

未來,公司仍將繼續加強與境內外公司及研發機構的交流與合作,為人類疾病預防做出更大貢獻,不斷提升公司效益,促進公司的可持續發展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account